Anti-fungal eradicates HIV from infected cells
October 17th 2013The topical anti-fungal agent ciclopirox causes HIV-infected cells to commit suicide by jamming up the cells’ powerhouse, the mitochondria, according to a recent study.The study, published in PLoS One, found that unlike currently available anti-HIV drugs, ciclopirox eradicates infectious HIV from cell cultures, with no rebound of virus when the drug is stopped.
Read More
Rivaroxaban reduced hospitalization by 1 day in pulmonary embolism cases
October 15th 2013In the treatment of pulmonary embolism (PE) in North American patients, rivaroxaban (Xarelto) reduced length of hospital stay by 1 full day compared to conventional dual therapy, according to data presented at the American College of Emergency Physicians scientific assembly, October 14-17, in Seattle.
Read More
Compared to patients with a principal diagnosis of heart failure, heart failure patients hospitalized with a diagnosis other than heart failure had lower rates of guideline-concordant care including assessment of left ventricular (LV) function or prescription for an ACE inhibitor or angiotensin receptor blocker (ARB) at time of discharge, according to a study published in the October 9 Journal of the American College of Cardiology.
Read More
Older adults with shingles experience more likely to ask for vaccine
October 14th 2013Personal knowledge of or experience with shingles may be a major driver in a consumer's decision about whether to receive the shingles vaccine, according to a Harris Interactive consumer awareness survey sponsored by Merck.
Read More
FDA approves first drug to treat 2 forms of pulmonary hypertension
October 10th 2013FDA approved riociguat (Adempas, Bayer HealthCare Pharmaceuticals) tablets for the treatment of adults with chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH and adults with pulmonary arterial hypertension (PAH).
Read More
EGFR inhibitor may provide convenient option for wild-type KRAS metastatic colorectal cancer
October 10th 2013Data from a phase 3 trial comparing panitumumab (Vectibix) to cetuximab (Erbitux) for the treatment of wild-type KRAS metastatic colorectal cancer (mCRC) in patients who have not responded to chemotherapy, provide the oncology community with important information on the use of EGFR inhibitors for patients with mCRC.
Read More
FDA addresses IV nutrition shortage with lipid injectable emulsion approval
October 8th 2013Under a priority review to help alleviate a drug shortage, FDA has approved lipid injectable emulsion, USP (Clinolipid, Baxter Healthcare) for intravenous feeding (parenteral nutrition) in adult patients, providing a source of calories and essential fatty acids for adult patients who are unable to eat or drink.
Read More
Chronic opioid use increases after bariatric surgery
October 8th 2013Chronic use of opioids among obese patients prior to bariatric surgery continues after bariatric surgery, and the dose. has been shown to be greater postoperatively than preoperatively, according to a recent study in the Journal of the American Medical Association.
Read More
Skipping antibiotic after hospital discharge leads to higher medical costs
October 6th 2013Patients who skip filling an antibiotic prescription after hospital discharge because of high out-of-pocket costs are at increased risk of rehospitalization and cost the healthcare system substantially more in the long term, according to a study published in the October issue of the American Journal of Managed Care.
Read More
Pertuzumab approved for early stage breast cancer under accelerated review
October 1st 2013Under priority review, FDA approved pertuzumab (Perjeta, Genentech, a member of the Roche Group) on September 30 as part of a complete treatment regimen for patients with early stage breast cancer before surgery.
Read More